 ROCKVILLE, Md.--BUSINESS WIRE--GlycoMimetics, Inc. Nasdaq: GLYC today reported its financial results for the third quarter ended September 30, 2020, and highlighted recent company events. Cash and cash equivalents at September 30, 2020 were 142.9 million. During the third quarter, both late-stage trials of uproleselan the Company-sponsored Phase 3 trial in relapsedrefractory AML patients as well as the NCIs study in newly-diagnosed AML patients fit for chemotherapy progressed in the 